Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Adenosine Diphosphate Ribose
100%
Polyadenosine
100%
Polymerase Inhibition
100%
Cavernous Nerve Injury
100%
Erectile Function
100%
Cavernous Nerve
100%
Nerve Crush Injury
100%
PARP Inhibitor (PARPi)
83%
INO-1001
66%
Treatment Group
50%
PARP Activation
50%
Intracavernous Pressure
50%
Inducible Nitric Oxide Synthase
33%
Sham
33%
Malondialdehyde
33%
Tyrosine Nitration
33%
Myeloperoxidase
33%
Penile Tissue
33%
Blood Pressure
16%
Immunohistochemistry
16%
Serum Levels
16%
Rat Model
16%
Tissue Level
16%
Tyrosine
16%
Neuroprotection
16%
Injury Model
16%
Polymerase
16%
High-performance Liquid Chromatography
16%
Sprague-Dawley Rats
16%
Nitrosative Stress
16%
Therapeutic Benefits
16%
Surgical Intervention
16%
3-group
16%
Massachusetts
16%
Inhibitor Treatment
16%
Pressure Ratio
16%
Erectile Dysfunction
16%
Psychogenic Erectile Dysfunction
16%
Erectile Response
16%
Cavernous Nerve Stimulation
16%
Pharmacology, Toxicology and Pharmaceutical Science
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
100%
Nerve Crush
100%
Nerve Injury
100%
Crush Trauma
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
83%
Treatment Group
50%
Malonaldehyde
33%
Poly(adenosine Diphosphate Ribose)
33%
Myeloperoxidase
33%
Erectile Dysfunction
33%
High Performance Liquid Chromatography
16%
Nitric Oxide Synthase
16%
Rat Model
16%
Neuroprotection
16%
Sprague Dawley Rat
16%
Inducible Nitric Oxide Synthase
16%
3 Nitrotyrosine
16%